Topical antibiotics: Therapeutic value or ecologic mischief?

Dermatologic Therapy

Volumn 22, Issue 5, 2009, Pages 398-406

  Del Rosso, James Q ^a,c   Kim, Grace K ^b  

^a Valley Hospital   (United States)

^b Mohave Skin and Cancer Clinics   (United States)

^c NONE   (United States)

Author keywords

Antibiotic resistance; Cutaneous infections; Topical antibiotics

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; BACITRACIN PLUS NEOMYCIN PLUS POLYMYXIN B; BENZALKONIUM CHLORIDE; BENZOYL PEROXIDE PLUS CLINDAMYCIN; CHLORHEXIDINE; CHLORHEXIDINE GLUCONATE; CLINDAMYCIN; CORTICOSTEROID; ERYTHROMYCIN; METICILLIN; NEOMYCIN; POVIDONE IODINE; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETAPAMULIN; TETRACYCLINE; TRICLOSAN; UNCLASSIFIED DRUG; VANCOMYCIN; WHITE PETROLATUM;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; CLINICAL TRIAL; CONTACT DERMATITIS; DERMATOLOGY; DRUG EFFICACY; HUMAN; IMPETIGO; INFECTION RISK; MEDICAL PRACTICE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OROPHARYNX; POSTOPERATIVE PERIOD; RECURRENT INFECTION; REVIEW; SKIN ALLERGY; SKIN FLORA; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; SURGICAL INFECTION; TREATMENT DURATION; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, CUTANEOUS; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; BACTERIA; DERMATOLOGY; DRUG RESISTANCE, BACTERIAL; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 69749114091     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2009.01256.x     Document Type: Review

References (78)

1. Ward A, Campoli-Richards DM. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs 1986 : 32 : 425 444.
2. Leyden JJ. Review of mupirocin ointment in the treatment of impetigo. Clin Pediatr 1992 : 31 : 49 53.
3. Rosen T, Waisman M. Topically administered clindamycin in the treatment of acne vulgaris and other dermatologic disorders. Pharmacotherapy 1981 : 1 : 201 205.
4. Shalita AR, Myers JA, Krochmal L, et al. The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosdphate yopical gel 1% for the treatment of acne vulgaris. J Drugs Dermatol 2005 : 4 : 48 46.
5. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005 : 153 : 395 403.
6. Del Rosso JQ, Leyden JJ, Thiboutot D, et al. Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologist. Cutis 2008 : 82 (2S[ii] 5 12.
7. Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin 2007 : 25 : 127 132.
8. Guay DRP. Treatment of bacterial skin and structure infections. Expert Opin Pharmacother 2003 : 4 : 1259 1275.
9. Levy SB. The challenge of antibiotic resistance. Sci Am 1998 : 278 : 46 53.
10. Esperson F. Resistance to antibiotics used in dermatologic practice. Br J Dermatol 1998 : 139 : 4 8.
11. Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983 : 8 : 41 45.
12. Eady AH, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003 : 12 : 813 831.
13. Finkelstein JA, Stille C, Nordin J, et al. Reduction in antibiotic use among US children 1996-2000. Pediatrics 2003 : 139 : 467 471.
14. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003 : 206 : 54 56.
15. Del Rosso JQ, Elston DM, Hirschmann J, et al. Summary report from the Scientific Panel on antibiotic use in dermatology: usage patterns, management challenges, and recommendations (poster presentation). American Academy of Dermatology Summer Meeting, San Diego, CA, July 26-30, 2006.
16. Bojar RA, Eady EA, Jones CE, et al. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1990 : 130 : 329 336.
17. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis 2007 : 79 (Suppl 6 9 25.
18. Levy RM, Huang EY, Rolling D, et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003 : 139 : 467 471.
19. Dreno B, Reynaud A, Moyse D, et al. Erythromycin-resistance of cutaneous bacterial flora in acne. Eur J Dermatol 2001 : 11 : 549 553.
20. Ross JL, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003 : 148 : 467 478.
21. Vowels BR, Feingold DS, Sloughfy C, et al. Effects of topical erythromycin on ecology of aerobic cutaneous bacterial flora. Antimicrob Agents Chemother 1996 : 40 : 2598 2604.
22. Mills O Jr., Thornsberry C, Cardin CW, et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002 : 82 : 260 265.
23. Harkaway KS, McGinley KJ, Foglia AN, et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol 1992 : 126 : 585 590.
24. Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989 : 121 : 51 57.
25. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Austral 1998 : 169 : 259 261.
26. Margolis DJ, Bowe WP, Hoffstad O, et al. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 2005 : 141 : 1132 1136.
27. Bowe WP, Hoffstad O, Margolis DJ. Upper respiratory tract infection in household contacts of acne patients. Dermatology 2007 : 215 : 213 218.
28. Schlessinger J, Menter A, Gold M, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol 2007 : 6 : 607 615.
29. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006 : 54 : 73 81.
30. Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008 : 59 : 792 800.
31. Zouboulis CC, Derumeaux L, Decroix J, et al. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation applied once daily and a combination lotion formulation applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000 : 143 : 498 505.
32. Cunliffe WJ, Holland KT, Bojar R, et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002 : 24 : 1117 1133.
33. Tanghetti EA, Popp KF. A current review of topical benzoyl peroxide: new perspectives on formulation and utilization. Dermatol Clinics 2009 : 27 : 17 24.
34. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from the global alliance to improve outcomes in acne. J Am Acad Dermatol 2003 : 49 (Suppl 1 S1 S38.
35. Leyden JJ, Wortzman M, Baldwin EK. Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. Cutis 2008 : 82 : 417 421.
36. Shalita AR, Rafal ES, Anderson D, et al. Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis 2003 : 72 : 167 172.
37. Del Rosso JQ. What is the role of benzoyl peroxide cleansers in acne management? J Clin Aesthet Dermatol 2008 : 41 : 48 51.
38. Del Rosso JQ. Benzoyl peroxide cleansers for the treatment of acne vulgaris: status report on available data. Cutis 2008 : 82 : 336 342.
39. Hirschmann JV. Antimicrobial therapy for skin infections. Cutis 2007 : 79 (Suppl 6 26 36.
40. Mulvey MR, MacDougall L, Cholin B, et al. and the Saskatchewan CA-MRSA Study Group. Community-associated methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis 2005 : 11 : 844 850.
41. Jones JC, Rogers TJ, Brookmeyer P, et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007 : 45 : 541 547.
42. Moy JA, Caldwell-Brown D, Lin AN, et al. Mupirocin-resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa. J Am Acad Dermatol 1990 : 22 : 893 895.
43. Elston DM. Topical antibiotics in dermatology: emerging patterns of resistance. Dermatol Clin 2009 : 27 : 25 31.
44. Jones RN, Li Q, Kohut B, et al. Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia. Diagn Microbiol Infect Dis 2006 : 54 : 63 71.
45. Fung S, O'Grady S, Kennedy C, et al. The utility of polysporin ointment in the eradication of methicillin-resistant Staphylococcus aureus colonization: a pilot study. Infect Control Hosp Epidemiol 2000 : 21 : 653 655.
46. Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol 2008 : 158 : 1077 1082.
47. Oranje AP, Chosidow O, Sacchidanand S, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology 2007 : 215 : 331 340.
48. Kosowska-Shick K, Clark C, Credito K, et al. Single- and multistep resistance selection studies on the activity od retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother 2006 : 50 : 765 769.
49. Kim G, Del Rosso JQ. Pharmacotherapy update: community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections: evaluation and management strategies. Skin & Aging 2008 : 16 : 36 38.
50. Sheth VM, Weltzul S. Postoperative topical antibiotic use. Dermatitis 2008 : 19 : 181 189.
51. Del Rosso JQ, Elston DM. Tackling the anterior nares and other sites of colonization: implications for the dermatologist. Cutis 2007 : 79 (Suppl 6 52 59.
52. Masenga J, Garbe C, Wagner J, et al. Staphylococcus aureus in atopic dermatitis and in nonatopic dermatitis. Int J Dermatol 1990 : 29 : 579 582.
53. Goodyear HM, Watson PJ, Egan SA, et al. Skin microflora of atopic eczema in first time hospital attendees. Clin Exper Dermatol 1993 : 18 : 300 304.
54. Aly R, Maibach HI, Shinefield HR, et al. Microbial flora of atopic dermatitis. Arch Dermatol 1977 : 113 : 780 782.
55. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974 : 90 : 525 530.
56. Wachs GN, Maibach HI. Cooperative double-blind trial of an antibiotic-corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976 : 95 : 323 328.
57. Lever R, Hadley K, Downey D, et al. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988 : 119 : 189 198.
58. Stalder JF, Fleury M, Sourisse M, et al. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994 : 131 : 536 540.
59. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992 : 27 : 29 34.
60. Hirschmann JV. Topical antibiotics in dermatology. Arch Dermatol 1988 : 124 : 1691 1700.
61. Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol 2006 : 155 : 680 687.
62. Elston DM. How to handle a CA-MRSA outbreak. Dermatol Clin 2009 : 27 : 43 48.
63. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006 : 193 : 172 179.
64. Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005 : 5 : 751 762.
65. Harbarth S, Dharan S, Liassine N, et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrobial Agents Chemother 1999 : 43 : 1412 1416.
66. Elston DM. Status update: hospital-acquired and community-acquired methicillin-resistant Staphylococcus aureus. Cutis 2007 : 79 (Suppl 6 37 42.
67. Kanazawa K, Ueda Y. Bacterial activity of chlorhexidine gluconate against recent clinical isolates of various bacterial species in Japan. Jpn J Antibiot 2004 : 57 : 449 464. (Pubitemid 39469556)
68. Kampf G, Jarosch R, Ruden H. Limited effectiveness of chlorhexidine based hand disinfectants against methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 1998 : 38 : 297 303.
69. Suller MT, Russell AD. Antibiotic and biocide resistance in methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. J Hosp Infect 1999 : 43 : 281 291.
70. Bamber AI, Neal TJ. An assessment of triclosan susceptibility in methicillin-resistant and methicillin-sensitive Staphylococcus aureus. J Hosp Infect 1999 : 41 : 107 109.
71. Brenwald NP, Fraise AP. Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 2003 : 55 : 141 144.
72. Suzuki J, Komatsuzawa H, Kozai K, et al. In vitro susceptibility of Staphylococcus aureus including MRSA to four disinfectants. ASDC J Dent Child 1997 : 64 : 260 263.
73. Griego RD, Zitelli JA. Intra-incisional prophylactic antibiotics for dermatologic surgery. Arch Dermatol 1998 : 134 : 688 692.
74. Whitaker DC, Grande DJ, Johnson SS. Wound infection rate in dermatologic surgery. J Dermatol Surg Oncol 1988 : 14 : 525 528.
75. Futoryan T, Grande D. Postoperative wound infection rates in dermatologic surgery. Dermatol Surg 1995 : 21 : 509 514.
76. Huether MJ, Griego RD, Brodland D, et al. Clindamycin for intraincisional antibiotic prophylaxis in dermatologic surgery. Arch Dermatol 2002 : 138 : 1145 1148.
77. Smack DP, Harrington AC, Dunn C, et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment: a randomized controlled trial. JAMA 1996 : 276 : 972 977.
78. Hirschmann JV. Antimicrobial prophylaxis in dermatologic surgery. Cutis 2007 : 79 (Suppl 6 43 51.